• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

2011年至2021年2型糖尿病患者的住院费用:中国西南部一项基于医院的多中心回顾性研究

In-patient expenditure between 2011 and 2021 for patients with type 2 diabetes mellitus: a hospital-based multicenter retrospective study in southwest China.

作者信息

He Yuxin, Tan Juntao, Tan Qingzhu, Zhang Xiao, Liu Yunyu, Tang Yang

机构信息

Department of Medical Administration, Affiliated Banan Hospital of Chongqing Medical University, Chongqing, China.

College of Medical Informatics, Chongqing Medical University, Chongqing, China.

出版信息

Front Public Health. 2025 Mar 10;13:1559424. doi: 10.3389/fpubh.2025.1559424. eCollection 2025.

DOI:10.3389/fpubh.2025.1559424
PMID:40129587
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11931030/
Abstract

BACKGROUND

Type 2 diabetes mellitus (T2DM) is a chronic non-infectious disease that seriously endangers human health. This study aimed to determine the main factors influencing the medical expenditure of T2DM patients and provide guidance for the allocation and control of medical expenditure.

METHODS

The homepage data of patients with T2DM were retrospectively collected from six tertiary hospitals in southwest China from January 2011 to December 2021. A multiple linear regression model was constructed to examine the factors associated with medical expenses per patient. Furthermore, the trends of medical expenditure according to other important measures and patient subgroups were described, and a proportional breakdown of medical expenditure was generated. All expenditure data were reported in Chinese Yuan (CNY), based on the 2021 value, and adjusted using the year-specific healthcare consumer price index.

RESULTS

A total of 45,237 patients with T2DM were analyzed in this study. Multiple linear regression showed that age, marital status, insurance type, length of stay, number of clinical visits, number of comorbidities, history of disease, history of surgery, smoking history, and the age-adjusted Charlson comorbidity index score were influencing factors of medical expenditure in patients with T2DM. Considering the overall average medical expenditure, diagnosis cost accounted for the largest proportion and was never <25% since 2011, showing a decreasing trend year by year. Among the types of comorbidity, hypertension was the most prevalent, followed by kidney disease and hyperlipidemia. In terms of the combination of comorbidities, medical expenditure was the highest for pulmonary infection+hypertension (24,360 CNY), followed by coronary heart disease+heart failure+hypertension (22,029 CNY).

CONCLUSIONS

Identifying the main factors influencing the medical expenditure of patients with T2DM can provide a reference for the medical security department to formulate reasonable compensation plans and for medical institutions to optimize treatment plans. Ultimately, this might reduce the financial burden of patients and relieve the pressure of medical insurance funds.

摘要

背景

2型糖尿病(T2DM)是一种严重危害人类健康的慢性非传染性疾病。本研究旨在确定影响T2DM患者医疗费用的主要因素,并为医疗费用的分配和控制提供指导。

方法

回顾性收集2011年1月至2021年12月中国西南地区6家三级医院T2DM患者的首页数据。构建多元线性回归模型,以检验与每位患者医疗费用相关的因素。此外,还描述了根据其他重要指标和患者亚组划分的医疗费用趋势,并生成了医疗费用的比例细分。所有支出数据均以人民币(CNY)为单位,基于2021年的价值,并使用特定年份的医疗消费者价格指数进行调整。

结果

本研究共分析了45237例T2DM患者。多元线性回归显示,年龄、婚姻状况、保险类型、住院时间、门诊次数、合并症数量、疾病史、手术史、吸烟史以及年龄调整后的Charlson合并症指数评分是T2DM患者医疗费用的影响因素。考虑总体平均医疗费用,诊断费用占比最大,自2011年以来从未低于25%,呈逐年下降趋势。在合并症类型中,高血压最为常见,其次是肾脏疾病和高脂血症。在合并症组合方面,肺部感染+高血压的医疗费用最高(24360元),其次是冠心病+心力衰竭+高血压(22029元)。

结论

确定影响T2DM患者医疗费用的主要因素,可为医保部门制定合理补偿方案以及医疗机构优化治疗方案提供参考。最终,这可能减轻患者的经济负担,缓解医疗保险基金的压力。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7c84/11931030/121cfee2a443/fpubh-13-1559424-g0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7c84/11931030/91670a8e9d56/fpubh-13-1559424-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7c84/11931030/9e4f39f3a1e5/fpubh-13-1559424-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7c84/11931030/4b3f41e622b8/fpubh-13-1559424-g0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7c84/11931030/121cfee2a443/fpubh-13-1559424-g0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7c84/11931030/91670a8e9d56/fpubh-13-1559424-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7c84/11931030/9e4f39f3a1e5/fpubh-13-1559424-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7c84/11931030/4b3f41e622b8/fpubh-13-1559424-g0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7c84/11931030/121cfee2a443/fpubh-13-1559424-g0004.jpg

相似文献

1
In-patient expenditure between 2011 and 2021 for patients with type 2 diabetes mellitus: a hospital-based multicenter retrospective study in southwest China.2011年至2021年2型糖尿病患者的住院费用:中国西南部一项基于医院的多中心回顾性研究
Front Public Health. 2025 Mar 10;13:1559424. doi: 10.3389/fpubh.2025.1559424. eCollection 2025.
2
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.对紫杉醇、多西他赛、吉西他滨和长春瑞滨在非小细胞肺癌中的临床疗效和成本效益进行的快速系统评价。
Health Technol Assess. 2001;5(32):1-195. doi: 10.3310/hta5320.
3
Clinical effectiveness and cost-effectiveness of continuous subcutaneous insulin infusion for diabetes: systematic review and economic evaluation.临床有效性和成本效益的连续皮下胰岛素输注治疗糖尿病: 系统评价和经济评估。
Health Technol Assess. 2010 Feb;14(11):iii-iv, xi-xvi, 1-181. doi: 10.3310/hta14110.
4
Diet, physical activity or both for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk of developing type 2 diabetes mellitus.饮食、体育活动或两者兼用,用于预防或延缓2型糖尿病高危人群发生2型糖尿病及其相关并发症。
Cochrane Database Syst Rev. 2017 Dec 4;12(12):CD003054. doi: 10.1002/14651858.CD003054.pub4.
5
The clinical effectiveness and cost-effectiveness of enzyme replacement therapy for Gaucher's disease: a systematic review.戈谢病酶替代疗法的临床疗效和成本效益:一项系统评价。
Health Technol Assess. 2006 Jul;10(24):iii-iv, ix-136. doi: 10.3310/hta10240.
6
What is the value of routinely testing full blood count, electrolytes and urea, and pulmonary function tests before elective surgery in patients with no apparent clinical indication and in subgroups of patients with common comorbidities: a systematic review of the clinical and cost-effective literature.在没有明显临床指征的患者和常见合并症患者亚组中,在择期手术前常规检测全血细胞计数、电解质和尿素以及肺功能测试的价值:对临床和成本效益文献的系统评价。
Health Technol Assess. 2012 Dec;16(50):i-xvi, 1-159. doi: 10.3310/hta16500.
7
Surveillance for Violent Deaths - National Violent Death Reporting System, 50 States, the District of Columbia, and Puerto Rico, 2022.暴力死亡监测——2022年全国暴力死亡报告系统,50个州、哥伦比亚特区和波多黎各
MMWR Surveill Summ. 2025 Jun 12;74(5):1-42. doi: 10.15585/mmwr.ss7405a1.
8
[Economic burden of esophageal cancer in China from 1996 to 2015: a systematic review].1996年至2015年中国食管癌的经济负担:系统评价
Zhonghua Liu Xing Bing Xue Za Zhi. 2017 Jan 10;38(1):102-109. doi: 10.3760/cma.j.issn.0254-6450.2017.01.020.
9
Dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus.二肽基肽酶(DPP)-4抑制剂和胰高血糖素样肽(GLP)-1类似物用于预防或延缓2型糖尿病高危人群发生2型糖尿病及其相关并发症。
Cochrane Database Syst Rev. 2017 May 10;5(5):CD012204. doi: 10.1002/14651858.CD012204.pub2.
10
Drugs for preventing postoperative nausea and vomiting in adults after general anaesthesia: a network meta-analysis.成人全身麻醉后预防术后恶心呕吐的药物:网状Meta分析
Cochrane Database Syst Rev. 2020 Oct 19;10(10):CD012859. doi: 10.1002/14651858.CD012859.pub2.

本文引用的文献

1
Impact of the COVID-19 pandemic on cancer healthcare utilization in southwestern China on March 2021.2021 年 3 月,COVID-19 大流行对中国西南部癌症医疗保健利用的影响。
Cancer Med. 2023 Jun;12(12):13821-13833. doi: 10.1002/cam4.6028. Epub 2023 May 11.
2
Attitudes and experiences of registered diabetes specialists in using health apps for managing type 2 diabetes: results from a mixed-methods study in Germany 2021/2022.德国注册糖尿病专家使用健康应用程序管理2型糖尿病的态度和经验:2021/2022年德国一项混合方法研究的结果
Arch Public Health. 2023 Mar 7;81(1):36. doi: 10.1186/s13690-023-01051-0.
3
Projected rapid growth in diabetes disease burden and economic burden in China: a spatio-temporal study from 2020 to 2030.
中国糖尿病疾病负担和经济负担的预计快速增长:一项2020年至2030年的时空研究
Lancet Reg Health West Pac. 2023 Feb 3;33:100700. doi: 10.1016/j.lanwpc.2023.100700. eCollection 2023 Apr.
4
A novel model for predicting prolonged stay of patients with type-2 diabetes mellitus: a 13-year (2010-2022) multicenter retrospective case-control study.一种预测 2 型糖尿病患者住院时间延长的新模型:一项 13 年(2010-2022 年)多中心回顾性病例对照研究。
J Transl Med. 2023 Feb 7;21(1):91. doi: 10.1186/s12967-023-03959-1.
5
Gestational Diabetes Mellitus and Its Implications across the Life Span.妊娠期糖尿病及其对全生命周期的影响。
Diabetes Metab J. 2023 May;47(3):333-344. doi: 10.4093/dmj.2022.0348. Epub 2023 Feb 8.
6
Challenges for Medicare and universal health care in Australia since 2000.2000 年以来澳大利亚的医疗保险和全民医疗保健面临的挑战。
Med J Aust. 2023 Apr 17;218(7):322-329. doi: 10.5694/mja2.51844. Epub 2023 Feb 4.
7
Smokers have increased risk of soft-tissue complications following primary elective TKA.吸烟者在接受初次择期全膝关节置换术后,发生软组织并发症的风险增加。
Arch Orthop Trauma Surg. 2023 Aug;143(8):4689-4695. doi: 10.1007/s00402-023-04771-8. Epub 2023 Jan 13.
8
Identifying and visualising multimorbidity and comorbidity patterns in patients in the English National Health Service: a population-based study.识别并可视化英国国家医疗服务体系中患者的多重疾病和共病模式:一项基于人群的研究。
Lancet Digit Health. 2023 Jan;5(1):e16-e27. doi: 10.1016/S2589-7500(22)00187-X. Epub 2022 Nov 29.
9
Analysis of Hospitalization Costs in Patients Suffering from Cerebral Infarction along with Varied Comorbidities.分析患有脑梗死并伴有不同合并症的患者的住院费用。
Int J Environ Res Public Health. 2022 Nov 16;19(22):15053. doi: 10.3390/ijerph192215053.
10
Diabetes Complications and Related Comorbidities Impair the Accuracy of FreeStyle Libre, a Flash Continuous Glucose Monitoring System, in Patients with Type 2 Diabetes.糖尿病并发症及相关合并症会损害2型糖尿病患者使用的瞬感扫描式葡萄糖监测系统(FreeStyle Libre)的准确性。
Diabetes Metab Syndr Obes. 2022 Nov 3;15:3437-3445. doi: 10.2147/DMSO.S381565. eCollection 2022.